Evaluation of memantine for the treatment of Alzheimer's disease

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 12, 2003, Pages 2305-2313

  Ferris, Steven H ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Dementia; Memantine; NMDA receptor antagonist

Indexed keywords

ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; DIZOCILPINE; DONEPEZIL; GALANTAMINE; GLUTAMIC ACID; GLYCOPROTEIN GP 120; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; RIVASTIGMINE; TACRINE;

AGITATION; ALZHEIMER DISEASE; BINDING AFFINITY; BINDING COMPETITION; CAREGIVER; CLINICAL TRIAL; COGNITION; CONFUSION; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ECONOMICS; FALLING; GLAUCOMA; HEADACHE; HEALTH CARE COST; HUMAN; INSOMNIA; MENTAL DETERIORATION; MULTIINFARCT DEMENTIA; NERVE CELL NECROSIS; NEUROMODULATION; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; PATHOLOGY; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT INDICATION; UNITED STATES; URINE INCONTINENCE; VERTIGO;

EID: 0345735594     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.12.2305     Document Type: Review

References (61)

1. EVANS DA, FUNKENSTEIN HH, ALBERT MS et al.: Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA (1989) 262(18):2551-2556.
2. BROOKMEYER R, GRAY S, KAWAS C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health (1998) 88(9):1337-1342.
3. HOYERT DL, ROSENBERG HM: Mortality from Alzheimer's disease: an update. Natl. Vital Stat. Rep. (1999) 47(20):1-8.
4. IRIZARRY MC, HYMAN BT: Alzheimer disease therapeutics. J. Neuropathol. Exp. Neurol. (2001) 60(10):923-928.
5. EMILIEN G, BEYREUTHER K, MASTERS CL, MALOTEAUX JM: Prospects for pharmacological intervention in Alzheimer disease. Arch. Neurol. (2000) 57(4):454-459.
6. WINBLAD B, PORITIS N: Memantine in severe dementia: results of the M-BEST Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry (1999) 14(2):135-146.
7. WIMO A, WINBLAD B, STÖFFLER A, WIRTH Y, MÖBIUS H: Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics (2003) 21(5):327-340.
8. REISBERG B, DOODY R, STÖFFLER A et al.: Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. (2003) 348(14):1333-1341.
9. REISBERG B, FERRIS S, MÖBIUS HJ, STÖFFLER A, SCHMITT F, DOODY RS: Long-term treatment with the NMDA antagonist memantine: results of a 24-week open-label extension study in moderate to severe Alzheimer's disease (abstract). Neurobiol. Aging (2002) 23(Suppl. 1):S555.
10. TARIOT PN, FARLOW M, GROSSBERG G et al.: Memantine/donepezil dual-therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease (abstract). J. Am. Geriatr. Soc. (2003) 51(S4):S225-S226.
11. GREENAMYRE JT, MARAGOS WF, ALBIN RL, PENNEY JB, YOUNG AB: Glutamate transmission and toxicity in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry (1988) 12(4):421-430.
12. WINBLAD B, MÖBIUS HJ, STÖFFLER A: Glutamate receptors as a target for Alzheimer's disease - are clinical results supporting the hope? J. Neural Transm. Suppl. (2002) 62:217-225.
13. WATKINS JC, EVANS RH: Excitatory amino acid transmitters. Annu. Rev. Pharmacol. Toxicol. (1981) 21:165-204.
14. DANYSZ W, ZAJACZKOWSKI W, PARSONS CG: Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. (1995) 6(5-6):455-474.
15. DOBLE A: The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. (1999) 81(3):163-221.
16. MALENKA RC, NICOLL RA: NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends Neurosci. (1993) 16(12):521-527.
17. ROTHMAN SM, OLNEY JW: Excitotoxicity and the NMDA receptor. Trends Neurosci. (1987) 10(7):299-302.
18. WENK GL, DANYSZ W, MOBLEY SL: Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res. (1994) 655(1-2):7-11.
19. MISZTAL M, FRANKIEWICZ T, PARSONS CG, DANYSZ W: Learning deficits induced by chronic intraventricular infusion of quinolinic acid - protection by MK-801 and memantine. Eur. J. Pharmacol. (1996) 296(1):1-8.
20. HARKANY T, ABRAHAM I, TIMMERMAN W et al.: Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur. J. Neurosci. (2000) 12(8):2735-2745.
21. DORAISWAMY PM: Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs (2002) 16(12):811-824.
22. ESCLAIRE F, LESORT M, BLANCHARD C, HUGON J: Glutamate toxicity enhances tau gene expression in neuronal cultures. J. Neurosci. Res. (1997) 49(3):309-318.
23. ZAJACZKOWSKI W, QUACK G, DANYSZ W: Infusion of(+) -MK-801 and memantine - contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Pharmacol. (1996) 296(3):239-246.
24. KORNHUBER J, WELLER M: Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry (1997) 41(2):135-144.
25. WENK GL, DANYSZ W, MOBLEY SL: MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmacol. (1995) 293(3):267-270.
26. MIGUEL-HIDALGO JJ, ALVAREZ XA, CACABELOS R, QUACK G: Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1-40). Brain Res. (2002) 958(1):210-221.
27. DANYSZ W, MÖBIUS H, PARSONS C, QUACK G, STÖFFLER A, WENK G: Memantine provides neuroprotection in animal models at therapeutically relevant doses. Am. J. Geriatr. Psychiatry (2002) 10(2 Suppl. 1):81 (Abstract).
28. CHEN HS, PELLEGRINI JW, AGGARWAL SK et al.: Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. (1992) 12(11):4427-4436.
29. TREMBLAY R, CHAKRAVARTHY B, HEWITT K et al.: Transient NMDA receptor inactivation provides long-term protection to cultured cortical neurons from a variety of death signals. J. Neurosci. (2000) 20(19):7183-7192.
30. PARSONS CG, DANYSZ W, QUACK G: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology (1999) 38(6):735-767.
31. KORNHUBER J, QUACK G: Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci. Lett. (1995) 195(2):137-139.
32. KORNHUBER J, BORMANN J, HUBERS M, RUSCHE K, RIEDERER P: Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur. J. Pharmacol. (1991) 206(4):297-300.
33. WESEMANN W, STURM G, FUNFGELD EW. Distribution of metabolism of the potential anti-parkinson drug memantine in the human. J. Neural Transm. Suppl. (1980) 16:143-148.
34. FREUDENTHALER S, MEINEKE I, SCHREEB KH, BOAKYE E, GUNDERT-REMY U, GLEITER CH: Influence of urine pH and urinary flow on the renal excretion of memantine. Br. J. Clin. Pharmacol. (1998) 46(6):541-546.
35. JAIN KK: Evaluation of memantine for neuroprotection in dementia. Expert Opin. Investig. Drugs (2000) 9(6):1397-1406.
36. WESEMANN W, SONTAG KH, MAJ J: [Pharmacodynamics and pharmacokinetics of memantine]. Arzneimittelforschung (1983) 33 (8):1122-1134.
37. WENK GL, QUACK G, MÖBIUS HJ, DANYSZ W: No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. (2000) 66(12):1079-1083.
38. HARTMANN S, MÖBIUS HJ: Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int. Clin. Psychopharmacol. (2003) 18(2):81-85.
39. PERICLOU A, VENTURA D, SHERMAN T, RAO N, ABRAMOWITZ W: A pharmacokinetic study of the NMDA receptor antagonist memantine and donepezil in healthy young subjects (abstract). J. Am. Geriatr. Soc. (2003) 51(S4):S225.
40. GÖRTELMEYER R, ERBLER H: Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung (1992) 42(7):904-913.
41. DITZLER K: Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung (1991) 41(8):773-780.
42. PANTEV M, RITTER R, GÖRTELMEYER R: Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Z. Gentopsychol. Psychiatr. (1993) 6:103-117.
43. GRAHAM S, LEE G, MÖBIUS HJ, MCDONALD S, WINBLAD B: Efficacy and tolerability of memantine in nursing home patients with moderate to severe dementia of the Alzheimer's type. Proc. 43rd New Clin. Drug Eval. Unit, Boca Raton, FL, USA (2003) (Abstract).
44. GALASK0 D, BENNETT D, SANO M et al.: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. (1997) 11(Suppl. 2):S33-S39.
45. GALASK0 DR, SCHMITT FA, JIN S et al.: Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease. Neurobiol. Aging (2000) 21 (Suppl. 1):S168 (Abstract).
46. REISBERG B, SCHNEIDER L, DOODY R et al.: Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis. Assoc. Disord. (1997) 11(Suppl. 3):8-18.
47. PANISSET M, ROUDIER M, SAXTON J, BOLLER F: Severe impairment battery. A neuropsychological test for severely demented patients. Arch. Neurol. (1994) 51(1):41-45.
48. SCHMITT FA, ASHFORD W, ERNESTO C et al.: The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. (1997) 11(Suppl. 2):S51-S56.
49. SCLAN SG, REISBERG B: Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int. Psychogeriatr. (1992) 4(Suppl. 1):55-69.
50. PARSONS CG, FRANKIEWICZ T, LAZAREWICZ JW, GADAMSKI R: Memantine enhances ischemic tolerance. Neurology (2001) 56(Suppl. 3):A340-A341 (Abstract).
51. ORGOGOZO JM, RIGAUD AS, STÖFFLER A, MÖBIUS HJ, FORETTE F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke (2002) 33(7):1834-1839.
52. WILCOCK G, MÖBIUS HJ, STÖFFLER A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int. Clin. Psychopharmacol. (2002) 17(6):297-305.
53. BANERJEE PK: Beneficial effects of memantine, a moderate affinity uncompetitive NMDA receptor antagonist, in experimental models of neuropathic pain. Neurology (2002) 58(Suppl. 3):A473-A474 (Abstract).
54. KIRBY LC, THE MEMANTINE STUDY GROUP: Memantine in the treatment of diabetics with painful peripheral neuropathy: a placebo-controlled trial. Pain Med. (2002) 3(2):182 (Abstract).
55. MAIER C, DERTWINKEL R, MANSOURIAN N et al.: Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain - results of a randomized double-blinded, placebo-controlled trial. Pain (2003) 103(3):277-283.
56. HARTWICK AT: Beyond intraocular pressure: neuroprotective strategies for future glaucoma therapy. Optom. Vis. Sci. (2001) 78(2):85-94.
57. LIPTON SA: Retinal ganglion cells, glaucoma and neuroprotection. Prog. Brain Res. (2001) 131:712-718.
58. NASKAR R, VORWERK CK, DREYER EB: Saving the nerve from glaucoma: memantine to caspaces. Semin. Ophthalmol. (1999) 14(3):152-158.
59. HONKANEN RA, BARUAH S, ZIMMERMAN MB et al.: Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectomy. Arch. Ophthalmol. (2003) 121(2):183-188.
60. HACHINSKI VC, ILIFF LD, ZILHKA E et al.: Cerebral blood flow in dementia. Arch. Neurol. (1975) 32(9):632-637.
61. ROSEN WG, TERRY RD, FULD PA, KATZMAN R, PECK A: Pathological verification of ischemic score in differentiation of dementias. Ann. Neurol. (1980) 7(5):486-488.